CLYM
NASDAQ HealthcareClimb Bio, Inc. - Common Stock
Biotechnology
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
�� 市场数据
| 价格 | $9.16 |
|---|---|
| 成交量 | 439,456 |
| 市值 | 624.57M |
| 贝塔系数 | -0.200 |
| RSI（14日） | 75.0 超买 |
| 200日均线 | $3.59 |
| 50日均线 | $6.86 |
| 52周最高 | $9.40 |
| 52周最低 | $1.13 |
| Forward P/E | -6.27 |
| Price / Book | 2.73 |
🎯 投资策略评分
CLYM 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (57/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CLYM in your text
粘贴任何文章、记录或帖子 — 工具将提取 CLYM 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.